FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
- Details
- Category: FDA
The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML.
FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
- Details
- Category: FDA
The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.
FDA warns of imposters sending consumers fake warning letters
- Details
- Category: FDA
The U.S. Food and Drug Administration is warning consumers about criminals forging FDA warning letters to target individuals who tried to purchase medicines online or over the phone. Based on the agency's experience with criminals posing as FDA employees, the FDA is concerned that these fake warning letters are linked to an international extortion scam. The FDA generally does not issue warning letters to individuals who purchase medicines online.
FDA takes steps to encourage more informative labeling on prescription drug and biological products' indications and usage
- Details
- Category: FDA
Today, the U.S. Food and Drug Administration issued a draft guidance to provide recommendations for consideration when drafting the Indications and Usage section of human drug and biological product labeling. The FDA regulations require the Indications and Usage section of drug labeling to state that the drug is indicated for the treatment, prevention, mitigation, cure or diagnosis of a disease or condition, or for the relief of the disease or condition’s symptoms.
FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy
- Details
- Category: FDA
The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.
FDA takes steps to foster greater efficiency in biosimilar development by reconsidering draft guidance on evaluating analytical studies
- Details
- Category: FDA
Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as written, was intended to provide advice for sponsors developing biosimilar products regarding the evaluation of analytical similarity between a proposed biosimilar product and a reference product. After considering public comments that the agency received about the draft guidance, the FDA determined it would withdraw the draft guidance as it gives further consideration to the scientific and regulatory issues involved.
FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales
- Details
- Category: FDA
The U.S. Food and Drug Administration today announced that it has warned nine online networks, operating a total of 53 websites, that they must stop illegally marketing potentially dangerous, unapproved and misbranded versions of opioid medications, including tramadol and oxycodone.
Companies who fail to correct the violations, as outlined in the warning letters, may be subject to enforcement action, including product seizure or injunction.
More Pharma News ...
- FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment
- FDA takes new steps to advance digital health, opening docket to solicit feedback on software products
- FDA approves novel preventive treatment for migraine
- FDA approves first epoetin alfa biosimilar for the treatment of anemia
- FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
- FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia
- FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems